

NYU Innovation Disclosure Form

At NYU's Technology Opportunities & Ventures (TOV), the Innovation Disclosure Form (IDF) is the first formal step in the process of identifying intellectual property and determining how to proceed with it. The process includes, for example, conducting searches for conflicting patents, copyrights and/or trademarks (as applicable), and evaluating the innovation's potential for commercialization by understanding the relevant market and competitive landscape. TOV reviews each disclosure to evaluate and determine, if applicable, a strategy to protect the innovation and to facilitate its commercialization to yield products to benefit society.

An IDF is a report and record that should be submitted when something new and useful has been invented or created. Completed IDFs are important legal documents serving as a record of innovation as well as the circumstances under which the innovation was made.

An IDF is treated by TOV as confidential and privileged because it is submitted for the purposes of seeking legal advice concerning patentability, copyrightability, etc., and such information is subject to legal and other review and confirmation. To ensure that the best strategy possible may be developed for your innovation, please keep it confidential until a decision by TOV has been made.¹

If a public disclosure (e.g.,submission of a manuscript, publication, oral presentation, a poster presentation, press release, etc.) of your innovation is planned or will be planned, please complete and submit an IDF well in advance of the disclosure. Failure to submit an IDF early to our office may have potential negative consequences.²

It is required that all fields of the IDF be completed. For guidance on how to complete this IDF, call TOV at (212) 263-8178.

TOV looks forward to learning more about your innovation and to working through this process with you.

Submit the completed IDF with original signatures to innovations@nyulangone.org.

Shilpa V. Patel, JD PhD Director, Intellectual Property Technology Opportunities & Ventures NYU Langone Health New York University One Park Avenue, 6th Floor New York, NY 10016 shilpa.patel@nyulangone.org patels33@nyu.edu

¹For example, for innovations that are patentable and for which patent protection is pursued, a patent application is not publicly available until it is published (18 months after filing) or the invention is publicly disclosed (e.g. publication (online or paper) of a manuscript or a conference presentation describing some or all aspects of the invention). Accordingly, prior to a patent application publication or public disclosure, the information in a submitted IDF will not be distributed except (a) to research sponsors as may be stipulated by contract, (b) to parties that are under attorney-client privilege or confidentiality agreements, or (c) as may be required by law.

²For example, for an innovation that is patentable, it must be novel, nonobvious, have written description, be enabled and be useful. In order for an invention to be novel, it must not have been disclosed or made available publicly. If an invention has been publicly disclosed, in the United States it may still be possible to pursue patent protection for an invention; however, most foreign patent rights will no longer be possible.



Α.	Innovatio	n Identifiers		
Title of the Innovation				
Date(s) of Innovation				
	— Innovation Field (check all that appl	v):	
	,	•••	<i>,</i>	
Therapeutic Diag	gnostic 🦳 Medica	I Device 🗌 🛛 H	lealthcare Information Te	echnology
Materials/Chemical	Ion-Medical Software	Research Tool	Manual/Protocol/Que	stionnaire 🗌
Reagent Electron	nics/Communications	Trademark	Copyright	Digital
Other (please describe):				

Β.

Potential Contributors

Please list all Potential Contributors involved in the research, development, and/or creation activities, and provide all requested information for each. If a contributor is not from NYU, please indicate that below. If patent protection is pursued, then actual inventorship will be determined by a patent attorney in accordance with federal patent law. The **Potential Contributor who is designated as the Contact Contributor will be the main contact for NYU TOV, and will be responsible for coordination and/or correspondence with other Potential Contributors when needed.**

	Potential Contribut (Contact Contribu		Potent	ial Contribut	or #2	Potent	ial Contribut	or #3
Full Name								
Department/Division at the time of the Innovation								
NYU Campus (SOM, WSq, NYU Abu Dhabi) or non-NYU Institution								
Home Address								
City, State, Zip Code								
Best Phone Contact								
NYU Email Address								
Personal E-mail Address								
Country of Citizenship								
NYU Employee # or Kerberos ID or NetID								
Is Contributor an awardee or sub-awardee on any federal grant(s), contract(s), or subcontract(s) related to this innovation	Awardee Sub-awardee	Both	Awardee	Sub-awardee	Both	Awardee	Sub-awardee	Both



В.

Potential Contributors - Continued

	Potentia	al Contribut	or #4	Potent	ial Contribut	tor #5	Potent	ial Contribut	or #6
Full Name									
Department/Division at the time of the Innovation									
NYU Campus (SOM, WSq, NYU Abu Dhabi) or non-NYU Institution									
Home Address									
City, State, Zip Code									
Best Phone Contact									
NYU Email Address									
Personal E-mail Address									
Country of Citizenship									
NYU Employee # or Kerberos ID or NetID									
Is Contributor an awardee or sub-awardee on any federal grant(s), contract(s), or subcontract(s) related to this innovation	Awardee	Sub-awardee	Both	Awardee	Sub-awardee	Both	Awardee	Sub-awardee	Both



С.

Innovation Details

 Describe the innovation, in as much detail as possible. (e.g. include materials and components; operative and preferred ranges for process/method parameters; concentrations of chemical compounds; technical details of software (e.g. system requirements, programming language, distribution code format)). Sketches, prints, photos, and any pertinent manuscripts should be included/attached when IDF is submitted.

2. What existing problem or unmet need does the innovation address and what advantages does it possess over current technologies/solutions? Describe all novel features of the innovation.

3. Specify the closest technologies known to you currently.





Innovation Details - Continued

4. List any knowledge you possess regarding existing patents, publications, or prior art. Please provide citations and or URLs. If you have questions, please contact us so that you may complete this.

5. At what stage of development is the innovation/solution? Specifically has the innovation been implemented in a computer program or online app, prototyped, scientifically studied, experimentally tested or clinically validated? If so, please describe and/or provide data, if relevant.

6. What is the research plan for the next two years relating to the innovation?

C	C. Innovation Details - Continu	ued				
7.	Has this innovation been publicly disclosed (e.g. publications, abstracts, appoint online [e.g. BioRxiv, ChemRxiv, arXiv, figshare], conferences, conference ab poster sessions, presentations, lectures, or other)?		Yes	No		
8.	Are any Potential Contributors on this form interested in pursuing a startup co based on this innovation?	ompany	Yes	No		
9.	Do you know of any companies that might be interested in this innovation?		Yes	No		
9a.	9a. If yes, please list the specific contacts if you have them, or simply list some companies that you think might be interested in this innovation.					
	Company Cit	y/State	Cont	tact Person		

NYU Langone Health

WYU

D.	D. Sources of Funding								
federal gran provided/su	earch that ga t(s), contract oported by fe , then certify deral award.	Yes	No						
If Yes, are a	any of the cor	ntributo	ors the primary or	sub-awardee	of the fede	eral funding?	Yes	No	
Primary Funding?	Sponsor(s)	Grant/Contract	Number(s):	Princi	pal Investigator:	Administe	ring Dept/Center:	
If awards and/or support was provided by another source not listed above (non-federal grants (e.g., private foundation), philanthro gifts, Institutional source, private investor, industry sponsor, etc.), please provide details:), philanthropic		
Award Sour	Award Source/Sponsor Award Number PI Date Funded		Date Funded		d to an entity other ′U, please specify				

Awaru Source/Sponsor	Awaru Number	P1	Date Fullded	than NYU, please specify

N	ULangone MYU Technolog	gy Opportuniti	ies & Venture	
	E. Internal and External Resources & Fur	nding		
1.	Do any of the Potential Contributors have an appointment with or funding from the U.S. Department of Veterans Affairs?	Yes	No	
2.	At the time of innovative contribution were any of the Potential Contributors a Howard Hughes Medical Institute (HHMI) Investigator?	Yes	No	
3.	Was the research that gave rise to the intellectual property supported by Colton Center Funding	Yes	No	
4.	4. At the time of innovative contribution were any of the Potential Contributors a member of the Perlmutter Cancer Center (PCC) or a full or associate member of a PCC Cancer Center Support Grant program (e.g., Cancer Cell Biology, Cancer Genome Dynamics, Epidemiology & Cancer Control, etc.)? Yes No			
4a.	If yes, please specify:			
5.	Was the innovation funded by CTSI?	Yes	No	
6.	Was the research that gave rise to the innovation supported by the Parekh Center of Neurogenerative Diseases?	Yes	No	
7.	Was any part of this innovation generated and/or developed outside of NYU?	Yes	No	
7a	If yes, please provide names of Potential Contributors and the place of employment and/or affiliation.			
8.	Was the innovation funded by any other internal NYU grant of program?	Yes	No	
8a.	If yes, please specify:			

F. Does the innovation relate to third party agreements and/or obligations?

1.	Were any materials that were used in the development of the innovation obtained from a third party?	Yes	No
2.	Were any materials that were used to generate/create the innovation subject to an MTA or purchase agreement?	Yes	No
3.	Was any third party owned equipment used?	Yes	No
4.	Does the research arise from a Sponsored Research Agreement?	Yes	No
5.	Are any other agreements applicable to this innovation?	Yes	No
5a.	. If yes, please specify:		



Submission acknowledgment section for NYU Langone Health employees. For all other NYU employees, please use page 9.

Submission Acknowledgment - NYU Langone Health Employees

Please sign below in the signature boxes (digital signature, ink, or electronic scanned signature). NYU Langone Health requires all Potential Contributors who are its faculty, officers, employees or students to sign.

I/We submit this Innovation Disclosure Form pursuant to the NYU Langone Health Statement of Policy on Intellectual Property Policy (effective December 15, 2021) and the NYU Langone Health Intellectual Property Agreement, both of which can be found on InsideHealth For NYU Langone Employees.

I/We have read and understood the above description of the TOV Innovation Disclosure Form submission process. I/We agree to provide assistance as TOV may reasonably request to obtain patents and develop the commercial value of the innovation, including but not limited to, signing documents as may be required for these purposes. I/We declare that this innovation disclosure is complete and accurate to the best of my (our) knowledge.

Signatures	Date

Signature of Department Chair

Signature of the Chair of the Department is mandatory

I have read and understand the foregoing disclosure:

The Chair of the Department:

Date

ULangone 🦞 NYU

Submission acknowledgment section for NYU employees. For NYU Langone Health employees, please use page 8.

Submission Acknowledgment - NYU Employees

Please sign below in the signature boxes (digital signature, ink, or electronic scanned signature). NYU requires all Potential Contributors who are its faculty, officers, employees or students to sign.

I/We submit this Innovation Disclosure Form pursuant to <u>NYU's Statement of Policy on Intellectual Property Policy</u> (effective December 15, 2021) which can be found on NYU's website.

I/We have read and understood the above description of the TOV Innovation Disclosure Form submission process. I/We agree to provide assistance as TOV may reasonably request to obtain patents and develop the commercial value of the innovation, including but not limited to, signing documents as may be required for these purposes. I/We declare that this innovation disclosure is complete and accurate to the best of my (our) knowledge.

Signatures	Date

Signature of Department Chair

Signature of the Chair of the Department is mandatory

I have read and understand the foregoing disclosure:

The Chair of the Department:

Date